Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,245) Arrow Down
Filter Results: (1,245) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,245)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (757)

Show Results For

  • All HBS Web  (1,245)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (757)
← Page 14 of 1,245 Results →
  • February 2009 (Revised December 2009)
  • Case

Merck: Global Health and Access to Medicines

By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Rangan, V. Kasturi, and Katharine Lee. "Merck: Global Health and Access to Medicines." Harvard Business School Case 509-048, February 2009. (Revised December 2009.)
  • July 2004 (Revised May 2005)
  • Case

Pfizer's Virtual CIO (Abridged)

By: F. Warren McFarlan and Brian DeLacey
Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details
Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry
Citation
Find at Harvard
Related
McFarlan, F. Warren, and Brian DeLacey. "Pfizer's Virtual CIO (Abridged)." Harvard Business School Case 305-018, July 2004. (Revised May 2005.)
  • Video

Said Darwazah

Said Darwazah, Executive Chairman and CEO of Hikma Pharmaceuticals PLC, speaks about the importance of hiring local employees to help lead the company’s expansions into new markets, particularly in the context of political crises such as the Arab Spring or health... View Details
  • September 2023 (Revised April 2024)
  • Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
  • April 2014
  • Case

Merrimack Pharmaceuticals, Inc. (A)

By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R&D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
  • October 2012
  • Case

Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)

By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
  • March 2008 (Revised June 2008)
  • Case

Sirtris Pharmaceuticals: Living Healthier, Longer

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
  • July 2010
  • Case

Metabical: Positioning and Communications Strategy for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details
Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug." Harvard Business School Brief Case 104-240, July 2010.
  • July 1989 (Revised December 1990)
  • Case

CIBA-GEIGY Pharmaceuticals: Pharma International

By: John A. Quelch
Examines the decision by Pharma International on whether to launch an antimalarial product in Nigeria and, if so, how that should be implemented. Involves commercial, ethical, and policy considerations. Rich in situation assessment data, the case refers to criticism of... View Details
Keywords: Ethics; Decision Choices and Conditions; Product Launch; Policy; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Citation
Educators
Purchase
Related
Quelch, John A. "CIBA-GEIGY Pharmaceuticals: Pharma International." Harvard Business School Case 589-108, July 1989. (Revised December 1990.)
  • April 2008 (Revised May 2009)
  • Case

Robert Wessman and Actavis' "Winning Formula"

Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with 11,000 people, active in 40 countries, global manufacturing, and $1.6 billion.... View Details
Keywords: Globalized Firms and Management; Business Growth and Maturation; Success; Transformation; Business Strategy; Pharmaceutical Industry; Iceland
Citation
Educators
Purchase
Related
Isenberg, Daniel J. Robert Wessman and Actavis' "Winning Formula". Harvard Business School Case 808-127, April 2008. (Revised May 2009.)
  • January 2016 (Revised January 2019)
  • Supplement

The Allergan Board Under Fire (B)

By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R&D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Corporate Governance; Investment Activism; Business and Stakeholder Relations; Business Model; Business and Shareholder Relations; Valuation; Pharmaceutical Industry
Citation
Purchase
Related
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
  • January 2016 (Revised January 2019)
  • Case

The Allergan Board Under Fire (A)

By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R&D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Management Teams; Business and Shareholder Relations; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
  • 15 Feb 2018
  • News

Does CVS–Aetna Spell the End of Business as Usual?

  • November 2019 (Revised April 2020)
  • Technical Note

The Life Sciences Revolution: A Technical Primer

By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich
For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be... View Details
Keywords: Science; Technological Innovation; Technology; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Pisano, Gary P., William J. Anderson, Amitabh Chandra, Clarissa Ceruti, and Stephanie Oestreich. "The Life Sciences Revolution: A Technical Primer." Harvard Business School Technical Note 620-054, November 2019. (Revised April 2020.)
  • June 2004
  • Case

Aventis SA (A): Planning for a Merger

By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
  • January 2001
  • Case

Merck Global Health Initiatives (B): Botswana

By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana
Citation
Educators
Purchase
Related
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
  • Research Summary

Research Interests

Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details

  • December 2008 (Revised April 2010)
  • Case

Proteus Biomedical: Making Pigs Fly

By: Richard G. Hamermesh, Lauren Barley and Ginger Graham
Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details
Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)
  • Article

One Obstacle to Curing Cancer: Patient Data Isn't Shared

By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
Citation
Register to Read
Related
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
  • November 2006
  • Case

Selling Biovail Short

By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details
Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada
Citation
Educators
Purchase
Related
Baker, Malcolm P., Chris Lombardi, and Aldo Sesia. "Selling Biovail Short." Harvard Business School Case 207-071, November 2006.
  • ←
  • 14
  • 15
  • …
  • 62
  • 63
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.